ArticleContemporary clinical trials communications2018

Extensions of the mTPI and TEQR designs to include non-monotone efficacy in addition to toxicity for optimal dose determination for early phase immunotherapy oncology trials.

Revathi Ananthakrishnan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.